Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer
Prostate cancer (PCa) still ranks as the second most frequently diagnosed cancer and metastatic castration-resistant prostate cancer (CRPC) is a foremost cause of men cancer death around the world. The aim of this work was to investigate the selectivity and efficacy of new drug combinations for CRPC...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , , , , , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
Bentham Science Publishers B.V.
2015
|
| Materias: | |
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 13748caa a22017417a 4500 | ||
|---|---|---|---|
| 001 | PAPER-24790 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518205642.0 | ||
| 008 | 190411s2015 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-84928944531 | |
| 024 | 7 | |2 cas |a flavopiridol, 131740-09-5, 146426-40-6; thalidomide, 50-35-1; alvocidib; Antineoplastic Agents; CPS 49; Drug Combinations; Flavonoids; Piperidines; Thalidomide | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a CPBUB | ||
| 100 | 1 | |a Zalazar, F. | |
| 245 | 1 | 0 | |a Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer |
| 260 | |b Bentham Science Publishers B.V. |c 2015 | ||
| 270 | 1 | 0 | |m De Siervi, A.; Laboratorio de Oncología Molecular y Nuevos Blancos Terapéuticos (IBYME-CONICET), Vuelta de Obligado 2490, Argentina |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics (2011) CA Cancer J. Clin | ||
| 504 | |a Shiota, M., Yokomizo, A., Fujimoto, N., Kuruma, H., Naito, S., Castration-resistant prostate cancer: Novel therapeutics pre- or post- taxane administration (2013) Curr. Cancer Drug Targets, 13, pp. 444-459 | ||
| 504 | |a Galsky, M.D., Vogelzang, N.J., Docetaxel-based combination therapy for castration-resistant prostate cancer (2010) Ann. Oncol., 21, pp. 2135-2144 | ||
| 504 | |a Saad, F., Miller, K., (2013) Treatment Options in Castration-Resistant Prostate Cancer: Current Therapies and Emerging Docetaxel-Based Regimens Urol Oncol. | ||
| 504 | |a Dahut, W.L., Gulley, J.L., Arlen, P.M., Liu, Y., Fedenko, K.M., Steinberg, S.M., Wright, J.J., Randomized Phase, I.I., Trial of docetaxel plus thalidomide in androgen-independent prostate cancer (2004) J. Clin. Oncol., 22, pp. 2532-2539 | ||
| 504 | |a Aragon-Ching, J.B., Li, H., Gardner, E.R., Figg, W.D., Thalidomide analogues as anticancer drugs (2007) Rec. Patents Anticancer Drug Discov., 2, pp. 167-174 | ||
| 504 | |a Corral, L.G., Haslett, P.A., Muller, G.W., Chen, R., Wong, L.M., Ocampo, C.J., Patterson, R.T., Kaplan, G., Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha (1999) J. Immunol., 163, pp. 380-386 | ||
| 504 | |a Corral, L.G., Kaplan, G., Immunomodulation by thalidomide and thalidomide analogues (1999) Ann. Rheum. Dis., 58, pp. I107-I113 | ||
| 504 | |a Ng, S.S., Macpherson, G.R., Gutschow, M., Eger, K., Figg, W.D., Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice (2004) Clin. Cancer Res., 10, pp. 4192-4197 | ||
| 504 | |a Ge, Y., Montano, I., Rustici, G., Freebern, W.J., Haggerty, C.M., Cui, W., Ponciano-Jackson, D., Gardner, K., Selective leukemic-cell killing by a novel functional class of thalidomide analogs (2006) Blood, 108, pp. 4126-4135 | ||
| 504 | |a Petrylak, D.P., Tangen, C.M., Van Veldhuizen, P.J., Goodwin, J.W., Twardowski, P.W., Atkins, J.N., Kakhil, S.R., Crawford, E.D., Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium (2010) BJU Int., 105, pp. 317-321 | ||
| 504 | |a Mathew, P., Dipaola, R., Taxane refractory prostate cancer (2007) J. Urol., 178, pp. S36-S41 | ||
| 504 | |a Kentepozidis, N., Soultati, A., Giassas, S., Vardakis, N., Kalykaki, A., Kotsakis, A., Papadimitraki, E., Georgoulias, V., Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: A Hellenic oncology research group multicenter phase II study (2012) Cancer Chemother. Pharmacol., 70, pp. 161-168 | ||
| 504 | |a Jeske, S., Tagawa, S.T., Olowokure, O., Selzer, J., Giannakakou, P., Nanus, D.M., Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer (2011) Urol Oncol., 29, pp. 676-681 | ||
| 504 | |a Sella, A., Yarom, N., Zisman, A., Kovel, S., Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer (2009) Oncology, 76, pp. 442-446 | ||
| 504 | |a Senderowicz, A.M., Small-molecule cyclin-dependent kinase modulators (2003) Oncogene, 22, pp. 6609-6620 | ||
| 504 | |a Blagosklonny, M.V., Flavopiridol, an inhibitor of transcription: Implications, problems and solutions (2004) Cell Cycle, 3, pp. 1537-1542 | ||
| 504 | |a Dai, Y., Grant, S., Cyclin-dependent kinase inhibitors (2003) Curr. Opin. Pharmacol., 3, pp. 362-370 | ||
| 504 | |a Newcomb, E.W., Flavopiridol: Pleiotropic biological effects enhance its anti-cancer activity (2004) Anticancer Drugs, 15, pp. 411-419 | ||
| 504 | |a Senderowicz, A.M., Headlee, D., Stinson, S.F., Lush, R.M., Kalil, N., Villalba, L., Hill, K., Phase, I., Trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms (1998) J. Clin. Oncol., 16, p. 2999 | ||
| 504 | |a Ge, Y., Byun, J.S., De Luca, P., Gueron, G., Yabe, I.M., Sadiq-Ali, S.G., Figg, W.D., Gardner, K., Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol (2008) Mol. Pharmacol., 74, pp. 872-883 | ||
| 504 | |a De Luca, P., Vazquez, E.S., Moiola, C.P., Zalazar, F., Cotignola, J., Gueron, G., Gardner, K., De Siervi, A., BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer (2011) Mol. Cancer Res., 9, pp. 1078-1090 | ||
| 504 | |a Sacca, P., Meiss, R., Casas, G., Mazza, O., Calvo, J.C., Navone, N., Vazquez, E., Nuclear translocation of haeme oxygenase-1 is associated to prostate cancer Br (2007) J. Cancer, 97, pp. 1683-1689 | ||
| 504 | |a Losiewicz, M.D., Carlson, B.A., Kaur, G., Sausville, E.A., Worland, P.J., Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275 (1994) Biochem. Biophys. Res. Commun, 201, pp. 589-595 | ||
| 504 | |a Carlson, B.A., Dubay, M.M., Sausville, E.A., Brizuela, L., Worland, P.J., Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells (1996) Cancer Res., 56, pp. 2973-2978 | ||
| 504 | |a Konig, A., Schwartz, G.K., Mohammad, R.M., Al-Katib, A., Gabrilove, J.L., The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines (1997) Blood, 90, pp. 4307-4312 | ||
| 504 | |a Kitada, S., Zapata, J.M., Andreeff, M., Reed, J.C., Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia (2000) Blood, 96, pp. 393-397 | ||
| 504 | |a Jiao, W., Lin, H.M., Datta, J., Braunschweig, T., Chung, J.Y., Hewitt, S.M., Rane, S.G., Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation (2008) Oncogene, 27, pp. 3156-3164 | ||
| 504 | |a Chen, Y.M., Shih, J.F., Lee, C.S., Chen, M.C., Lin, W.C., Tsai, C.M., Perng, R.P., Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel (2003) Lung Cancer, 39, pp. 209-214 | ||
| 520 | 3 | |a Prostate cancer (PCa) still ranks as the second most frequently diagnosed cancer and metastatic castration-resistant prostate cancer (CRPC) is a foremost cause of men cancer death around the world. The aim of this work was to investigate the selectivity and efficacy of new drug combinations for CRPC. We combined three compounds: paclitaxel (PTX: taxane that inhibits microtubule polymerization); 2-(2,4-Difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49; redox-reactive thalidomide analog with anti-angiogenic properties) and flavopiridol (flavo: semi-synthetic flavonoid that inhibits cyclin dependent kinases). We assessed CPS49-flavo or -PTX combinations cytotoxicity in a panel of PCa cell lines and PC3 xenografts. We found that CPS49 enhanced flavo or PTX cytotoxicity in human PCa cell lines while showed resistance in a non-tumor cell line. Furthermore, xenografts generated by inoculation of human prostate carcinoma PC3 cells in nu/nu mice showed that CPS49/flavo administration reduced tumor growth both after 2 weeks of co-treatment and after 1 week of pretreatment with a low dose of flavo followed by 2 weeks of co-treatment. PTX and CPS49 combination did not significantly reduce tumor growth in PC3 xenografts. Histological analysis of xenograft PC3 tumor samples from CPS49/flavo combination showed extensive areas of necrosis induced by the treatment. RT-qPCR array containing 23 genes from PC3 cells or PC3 xenografts exposed to CPS49/flavo combination showed that this treatment shut down the expression of several genes involved in adhesion, migration or invasion. In summary, the antitumor activity of CPS49 or flavopiridol was improved by the combination of these compounds and using half dose of that previously reported. Hence, CPS49-flavo combination is a promising new alternative for PCa therapy. © 2015 Bentham Science Publishers. |l eng | |
| 593 | |a Laboratorio de Oncología Molecular y Nuevos Blancos Terapéuticos, Instituto de Biología y Medi-cina Experimental (IBYME-CONICET, Buenos Aires, Argentina | ||
| 593 | |a Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health, Bethesda, United States | ||
| 593 | |a Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, United States | ||
| 593 | |a Departamento de Patología, Academia Nacional de Medicina, Buenos Aires, Argentina | ||
| 593 | |a Laboratorio de inflamación y cáncer, Departamento de Química Biológica, Universidad de Buenos Aires (UBA), IQUIBICEN - CONI-CET, Buenos Aires, Argentina | ||
| 593 | |a Laboratorio de Fisiopatología de la Inmunidad Innata, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técni-cas (CONICET), Argentina | ||
| 690 | 1 | 0 | |a CPS49 |
| 690 | 1 | 0 | |a FLAVOPIRIDOL |
| 690 | 1 | 0 | |a PACLITAXEL |
| 690 | 1 | 0 | |a PRECLINICAL STUDY |
| 690 | 1 | 0 | |a PROSTATE CANCER |
| 690 | 1 | 0 | |a XENOGRAFTS |
| 690 | 1 | 0 | |a ANTINEOPLASTIC AGENT |
| 690 | 1 | 0 | |a CPS 49 |
| 690 | 1 | 0 | |a FLAVOPIRIDOL |
| 690 | 1 | 0 | |a UNCLASSIFIED DRUG |
| 690 | 1 | 0 | |a ANTINEOPLASTIC AGENT |
| 690 | 1 | 0 | |a CPS 49 |
| 690 | 1 | 0 | |a DRUG COMBINATION |
| 690 | 1 | 0 | |a FLAVONOID |
| 690 | 1 | 0 | |a FLAVOPIRIDOL |
| 690 | 1 | 0 | |a PIPERIDINE DERIVATIVE |
| 690 | 1 | 0 | |a THALIDOMIDE |
| 690 | 1 | 0 | |a ANIMAL EXPERIMENT |
| 690 | 1 | 0 | |a ANIMAL MODEL |
| 690 | 1 | 0 | |a ANIMAL TISSUE |
| 690 | 1 | 0 | |a ANTINEOPLASTIC ACTIVITY |
| 690 | 1 | 0 | |a APOPTOSIS |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a CANCER STAGING |
| 690 | 1 | 0 | |a CELL ADHESION |
| 690 | 1 | 0 | |a CELL INVASION |
| 690 | 1 | 0 | |a CELL MIGRATION |
| 690 | 1 | 0 | |a CELL VIABILITY |
| 690 | 1 | 0 | |a CLONOGENIC ASSAY |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a CYTOTOXICITY |
| 690 | 1 | 0 | |a DRUG EFFICACY |
| 690 | 1 | 0 | |a HISTOLOGY |
| 690 | 1 | 0 | |a HUMAN |
| 690 | 1 | 0 | |a HUMAN CELL |
| 690 | 1 | 0 | |a LOW DRUG DOSE |
| 690 | 1 | 0 | |a MALE |
| 690 | 1 | 0 | |a MICROSCOPY |
| 690 | 1 | 0 | |a MOUSE |
| 690 | 1 | 0 | |a NONHUMAN |
| 690 | 1 | 0 | |a PROSTATE CANCER |
| 690 | 1 | 0 | |a REAL TIME POLYMERASE CHAIN REACTION |
| 690 | 1 | 0 | |a REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION |
| 690 | 1 | 0 | |a RNA ISOLATION |
| 690 | 1 | 0 | |a TUMOR GROWTH |
| 690 | 1 | 0 | |a TUMOR VOLUME |
| 690 | 1 | 0 | |a ANALOGS AND DERIVATIVES |
| 690 | 1 | 0 | |a ANIMAL |
| 690 | 1 | 0 | |a CELL SURVIVAL |
| 690 | 1 | 0 | |a DOSE RESPONSE |
| 690 | 1 | 0 | |a DRUG COMBINATION |
| 690 | 1 | 0 | |a DRUG EFFECTS |
| 690 | 1 | 0 | |a NUDE MOUSE |
| 690 | 1 | 0 | |a PATHOLOGY |
| 690 | 1 | 0 | |a PROSTATIC NEOPLASMS |
| 690 | 1 | 0 | |a TREATMENT OUTCOME |
| 690 | 1 | 0 | |a TUMOR CELL LINE |
| 690 | 1 | 0 | |a MUS |
| 690 | 1 | 0 | |a ANIMALS |
| 690 | 1 | 0 | |a ANTINEOPLASTIC AGENTS |
| 690 | 1 | 0 | |a ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS |
| 690 | 1 | 0 | |a APOPTOSIS |
| 690 | 1 | 0 | |a CELL LINE, TUMOR |
| 690 | 1 | 0 | |a CELL SURVIVAL |
| 690 | 1 | 0 | |a DOSE-RESPONSE RELATIONSHIP, DRUG |
| 690 | 1 | 0 | |a DRUG COMBINATIONS |
| 690 | 1 | 0 | |a FLAVONOIDS |
| 690 | 1 | 0 | |a HUMANS |
| 690 | 1 | 0 | |a MALE |
| 690 | 1 | 0 | |a MICE |
| 690 | 1 | 0 | |a MICE, NUDE |
| 690 | 1 | 0 | |a PIPERIDINES |
| 690 | 1 | 0 | |a PROSTATIC NEOPLASMS |
| 690 | 1 | 0 | |a THALIDOMIDE |
| 690 | 1 | 0 | |a TREATMENT OUTCOME |
| 653 | 0 | 0 | |a cps 49 |
| 700 | 1 | |a De Luca, P. | |
| 700 | 1 | |a Gardner, K. | |
| 700 | 1 | |a Figg, W.D. | |
| 700 | 1 | |a Meiss, R. | |
| 700 | 1 | |a Spallanzani, R.G. | |
| 700 | 1 | |a Vallecorsa, P. | |
| 700 | 1 | |a Elguero, B. | |
| 700 | 1 | |a Cotignola, J. | |
| 700 | 1 | |a Vazquez, E. | |
| 700 | 1 | |a De Siervi, A. | |
| 773 | 0 | |d Bentham Science Publishers B.V., 2015 |g v. 16 |h pp. 553-563 |k n. 6 |p Curr. Pharm. Biotechnol. |x 13892010 |t Current Pharmaceutical Biotechnology | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-84928944531&doi=10.2174%2f138920101606150407114407&partnerID=40&md5=b31c9974af9771fef86628ddccad5fe8 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.2174/138920101606150407114407 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_13892010_v16_n6_p553_Zalazar |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_13892010_v16_n6_p553_Zalazar |y Registro en la Biblioteca Digital |
| 961 | |a paper_13892010_v16_n6_p553_Zalazar |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 85743 | ||